SCHEMBL20488268

SCHEMBL20488268

CC(=O)C(Cc1ccc(S(=O)(=O)N(C)C)cc1)C(C)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
LMNA P02545 3/20 0.47
ADAMTS5 Q9UNA0 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
MAPT P10636 2/20 0.42
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 1/20 0.41
ABCC9 O60706 1/20 0.41
ABCC8 Q09428 1/20 0.41
KCNJ11 Q14654 1/20 0.41
KCNJ8 Q15842 1/20 0.41
CYP2C19 P33261 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20488845 0.88 ABCC9 (0.45) ALDH1A1LMNAADAMTS5SMN1; SMN2HTT
SCHEMBL19249371 0.87 L3MBTL1 (0.46) ALDH1A1LMNASMN1; SMN2HTTKDM4E
SCHEMBL20488243 0.84 LMNA (0.46) ALDH1A1LMNASMN1; SMN2HTTKDM4E
SCHEMBL20488824 0.82 ALDH1A1 (0.40) ALDH1A1LMNAADAMTS5SMN1; SMN2HTT
SCHEMBL20488825 0.82 ALDH1A1 (0.40) ALDH1A1LMNAADAMTS5SMN1; SMN2HTT
SCHEMBL3787450 0.81 ENPP2 (0.45) ALDH1A1LMNASMN1; SMN2TSHR
SCHEMBL9317096 0.80 LDHA (0.52) LMNACYP2C9TSHR
SCHEMBL12338346 0.79 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2HTTKDM4E
SCHEMBL21791585 0.78 L3MBTL1 (0.39) ALDH1A1LMNAKDM4ETSHRMAPT
SCHEMBL19249688 0.75 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
WO-2018157190-A9 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-10-25 WO disclosed
WO-2018157190-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF LOX, DAO, AADAC ALDH1A1 301/4885LMNA 1069/4885ADAMTS5 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.